In the current application, PEI-PEG-RGD targeted gene carrier was synthesized and characterized. The constructed plasmid encoding sFllt-1 was carried to angiogenic dermal microvascular endothelial cells. The in vivo studies demonstrated that expressed sFlt-1 carried by this delivery system delayed tumor growth and increased survival rate of animal. Therefore, PEI-PEG-RGD/pCMV- sFlt-1 complex can be useful to develop tumor specific anti-angiogenic gene therapy. In addition, combination of IL-2 and sFlk-1 plasmid was constructed. The in vitro and in vivo studies demonstrated excellent efficiency of anti-tumor activity. In this renewal application, we propose to deliver siRNA for silencing VEGF and VEGF receptors. RGD will be conjugated to the reducible polymer, poly (CBA-DAH), which is known to be non-toxic and greatly enhances transfection in several cell lines. RGD-chol-R9C will also be synthesized, since chol-R9C has demonstrated high transfection of siRNA. In addition, RGD- PEG-water soluble lipopolymer (WSLP) will be designed as WSLP has been proven an excellent carrier in this laboratory. Extensive in vitro and in vivo animal studies will be carried out with these RGD-conjugated polymers complexed with siRNA. Inhibition of tumor growth in murine prostate and breast adenocarcinoma models will be proven in the results. The obtained data can be utilized for the design of siRNA delivery to treat cancer patients.

Public Health Relevance

Three newly designed polymers will be conjugated with RGD. It is expected that both in vitro and in vivo studies will present positive results for siRNA delivery, which can be applied to tumor treatment.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Bioengineering, Technology and Surgical Sciences Study Section (BTSS)
Program Officer
Fu, Yali
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Utah
Schools of Pharmacy
Salt Lake City
United States
Zip Code
Florinas, Stelios; Kim, Jaesung; Nam, Kihoon et al. (2014) Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. J Control Release 183:1-8
Kim, J; Nam, H Y; Choi, J W et al. (2014) Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer. Gene Ther 21:476-83
Lee, Cho-Hee; Kasala, Dayananda; Na, Youjin et al. (2014) Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression. Biomaterials 35:5505-16
Kim, Hyun Ah; Nam, Kihoon; Kim, Sung Wan (2014) Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery. Biomaterials 35:7543-52
Lee, Young Sook; Kim, Sung Wan (2014) Bioreducible polymers for therapeutic gene delivery. J Control Release 190:424-39
Kasala, Dayananda; Choi, Joung-Woo; Kim, Sung Wan et al. (2014) Utilizing adenovirus vectors for gene delivery in cancer. Expert Opin Drug Deliv 11:379-92
Florinas, Stelios; Nam, Hye Yeong; Kim, Sung Wan (2013) Enhanced siRNA delivery using a combination of an arginine-grafted bioreducible polymer, ultrasound, and microbubbles in cancer cells. Mol Pharm 10:2021-30
Kim, Hyun Ah; Nam, Kihoon; Lee, Minhyung et al. (2013) Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy. J Control Release 171:1-10
Kim, Jaesung; Li, Yi; Kim, Sung Wan et al. (2013) Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex. Biomaterials 34:4622-31
Choi, J-W; Kang, E; Kwon, O-J et al. (2013) Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy. Gene Ther 20:880-92

Showing the most recent 10 out of 30 publications